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Among human natural killer (NK) cell intermediates
in secondary lymphoid tissue (SLT), stage 3
CD34CD117+CD161+CD94 immature NK (iNK)
cells uniquely express aryl hydrocarbon receptor
(AHR) and interleukin-22 (IL-22), supporting a role in
mucosal immunity. The mechanisms controlling
proliferation and differentiation of these cells are
unknown. Here we demonstrate that the IL-1
receptor IL-1R1 was selectively expressed by
a subpopulation of iNK cells that localized proximal
to IL-1b-producing conventional dendritic cells
(cDCs) within SLT. IL-1R1hi iNK cells required contin-
uous exposure to IL-1b to retain AHR and IL-22
expression, and they proliferate in direct response
to cDC-derived IL-15 and IL-1b. In the absence of
IL-1b, a substantially greater fraction of IL-1R1hi
iNK cells differentiated to stage 4 NK cells and
acquired the ability to kill and secrete IFN-g. Thus,
cDC-derived IL-1b preserves and expands IL-1R1hi
IL-22+AHR+ iNK cells, potentially influencing human
mucosal innate immunity during infection.
INTRODUCTION
Natural killer (NK) cells comprise a unique, diverse set of lympho-
cytes with emerging roles in the innate and adaptive immune
response (Sun and Lanier, 2009). Within secondary lymphoid
tissue (SLT), human NK cells appear to proceed through
five discrete states of developmental maturity, starting as multi-
potent CD34+ pro-NK cells and eventually progressing to func-tionally competent mature NK cells (Freud et al., 2005; Freud
et al., 2006). Our laboratory initially characterized four stages
of NK cell development in SLT in terms of lineage commitment,
response to cytokines, and NK cell effector function (Freud
et al., 2006). CD34+CD117 stage 1 pro-NK cells and
CD34+CD117+ stage 2 pre-NK cells retain the potential for differ-
entiation into T cells and dendritic cells (DCs), whereas
CD34CD117+CD94 stage 3 immature NK (iNK) cells and
CD34CD117+/CD94+ stage 4 mature NK cells appear to be
exclusively committed to the NK cell lineage. In addition, a fifth
and seemingly final stage of NK cell development has recently
been described in SLT, characterized by acquisition of CD16
and killer cell immunoglobulin (Ig)-like receptors, with a surface
antigen repertoire highly similar to that of peripheral blood
CD56dim NK cells (Freud and Caligiuri, 2006; Romagnani et al.,
2007). Stage 3 cells have been classified as immature because
they lack certain NK cell surface receptors, the capacity for
IFN-g production, and the cytolytic activity, which are all charac-
teristic of mature NK cells, including the more differentiated
stage 4 NK cells (Freud et al., 2006).
Resting stage 3 iNK cells found in human tonsil constitutively
express interleukin-22 (IL-22) (Cupedo et al., 2009; Hughes
et al., 2009), a cytokine implicated in mucosal immunity (Wolk
et al., 2004). ‘‘NK-22’’ cells found in mucosa-associated
lymphoid tissue (MALT) express the aryl hydrocarbon receptor
(AHR) (Cella et al., 2009). These data suggest that stage 3 iNK
cells within SLTmay have an important role inmucosal immunity.
IL-22+ iNK cells from human fetal lymph node possess lymphoid
tissue inducer (LTi) activity and a phenotype identical to that of
LTi cells (Cupedo et al., 2009). More recently, Crellin et al.
demonstrated LTi-like function within the CD127+ subset of
this LinCD117+CD161+ population (Crellin et al., 2010).
Indeed, stage 3 iNK cells represent the most abundant NK cell
developmental intermediate in human SLT (see Figure S1 avail-
able online). Conceivably, microbial invasion of MALT requiresImmunity 32, 803–814, June 25, 2010 ª2010 Elsevier Inc. 803
Figure 1. IL-1R1 Expression during NK Cell
Development
(A) IL-1R1 mRNA expression ex vivo in flow cy-
tometry purified human stage 1–4 SLT NK devel-
opmental intermediates assessed via real-time
PCR. Fold difference in IL-1R1 mRNA is relative
to that in stage 1, arbitrarily normalized to 1 (n = 4).
(B–D) Total CD3CD19 tonsillar mononuclear
cells were stained for surface expression of
CD34, CD117, CD94, and IL-1R1 and gated for
each stage as described (Freud et al., 2006).
(B) Histograms show IL-1R1 (filled) and isotype
(unfilled) surface staining in stage 2 (top) or stage
3 (bottom) cells from a representative donor
(n = 4).
(C and D) Shown within each gated SLT NK devel-
opmental intermediate population are the average
percent of cells with IL-1R1 surface expression
(n = 4) (C) and the density of IL-1R1 surface
expression (D), as represented by the ratio of IL-
1R1 mean fluorescence intensity (MFI) to isotype
MFI (n = 6). Data in (A), (C), and (D) are presented
as mean ± standard error of the mean (SEM;
*p% 0.05; **p% 0.005; ***p% 0.0005).
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IL-1b Expands and Sustains IL-22+ iNK Cellsan expansion of the IL-22+ stage 3 iNK cell for effective early
mucosal defense (Cupedo et al., 2009; Hughes et al., 2009).
Under such circumstances, expansion of the IL-22+ stage 3 pop-
ulation would need to occur withminimal differentiation to IFN-g-
producing stage 4 mature NK cells. Likewise, the architecture of
SLT can be drastically altered by excessive inflammation caused
by acute microbial infections and needs to be regenerated in
order to restore the SLT microenvironment. During this process,
LTi cells must proliferate and upregulate their expression
of molecules such as lymphotoxin (LT) a1b2 in order to initiate
tissue reorganization (Junt et al., 2008). The signal(s) that regu-
late expansion and differentiation of the stage 3 iNK cell popula-
tion are unknown and were investigated in this report. Here we
show that the IL-1 receptor IL-1R1 was selectively expressed
by a subpopulation of stage 3 iNK cells. In vitro, IL-1b was
required to retain AHR and IL-22 expression in IL-1R1hi iNK cells.
In the absence of IL-1b, a substantially greater fraction of IL-
1R1hi iNK cells differentiated to stage 4 NK cells capable of cyto-
toxicity and IFN-g secretion. These stage 3 iNK cells localized
proximal to IL-1b-producing conventional dendritic cells
(cDCs) within SLT and proliferated in direct response to cDC-
derived IL-15 and IL-1b. Together, our findings demonstrate
a role for IL-1b as a factor that influences the homeostasis of
human IL-22+ stage 3 iNK cells and suggest a potential physio-
logical role for CD11chiIL-1b+ cDCs in regulating expansion of
this IL-1R1hi subpopulation of stage 3 iNK cells in SLT.
RESULTS
Robust Expression of IL-R1 Surface Protein
Is Restricted to Stage 3 iNK Cells in SLT
IL-1b is released bymonocytes, macrophages, and DCs in direct
response to microbial invasion (Ikejima et al., 1984) and
promotes T helper 17 (Th17) cell homeostasis (Chung et al.,804 Immunity 32, 803–814, June 25, 2010 ª2010 Elsevier Inc.2009). We postulated that IL-1bmay serve a similar role in stage
3 iNK cell homeostasis within SLT. We therefore assayed flow
cytometry purified stage 1–4 NK developmental intermediates
from human tonsil for expression of IL-1R1 mRNA using real-
time reverse transcriptase-polymerase chain reaction (RT-
PCR). As shown in Figure 1A, significant IL-1R1 mRNA expres-
sion was confined to stage 2 pre-NK cells and stage 3 iNK cells.
In particular, IL-1R1 mRNA increased at least 38 ± 2.6-fold
between stages 1 and 2 and increased 49.2 ± 2.46-fold in stage
3 iNK cells over that seen in stages 1 or 4, where expression was
negligible. Thus, IL-1R1mRNA is selectively and abundantly ex-
pressed within stages 2 and 3 of human NK cell development.
Using flow cytometry, we next determined whether stage 2
pre-NK cells and stage 3 iNK cells from SLT display IL-1R1 cell
surface protein. Whereas %20% of stage 2 pre-NK cells ex-
pressed IL-1R1 surface protein,R70% of stage 3 iNK cells ex-
pressed IL-1R1 (Figures 1B and 1C). Notably, <10% of stage 4
mature NK cells expressed IL-1R1, data consistent with the
restricted manner in which IL-1R1 mRNA was expressed. The
ratio of IL-1R1 mean fluorescence intensity (MFI) to isotype
control MFI, which was used to gauge the relative density of
IL-1R1 expression on IL-1R1hi cells, was more than 3.01 ±
0.31-fold higher on stage 3 iNK cells when compared to stage
2 pre-NK cells (Figure 1D). Collectively, these findings indicate
that, among human SLT NK developmental intermediates,
high-density surface expression of IL-1R1 protein is only found
on a majority of stage 3 iNK cells.
IL-22 and AHR Are Restricted to the IL-1R1hi
Subpopulation of Stage 3 iNK Cells in SLT
It has been shown previously that freshly isolated, unstimulated
stage 3 iNK cells may have LTi-like properties and constitutively
express IL-22, RAR-related orphan receptor C (RORC), and
AHR (Cella et al., 2009; Cupedo et al., 2009; Hughes et al.,
Figure 2. IL-1R1hi and IL-1R1lo Subpopulations of Stage 3 iNK Cells Ex Vivo
(A–C) Tonsillar mononuclear cells were stained ex vivo for surface expression of CD117, IL-1R1, and intracellular IL-22 (B and C).
(A) Gated on Lin (CD3CD14CD16CD19CD34CD94) lymphocytes, dot plot indicates gates for IL-1R1hi (top) or IL-1R1lo (bottom) subpopulations of
CD117+ stage 3 iNK cells, as sorted in a representative donor (n = 18).
(B and C) Gating is as indicated in (A); histograms depict staining with isotype (unfilled) or a-IL-22 (filled) antibody in a representative donor (n = 5).
(D) IL-22 andAHRmRNAmeasured via real-time PCR ex vivo in flow cytometry sorted IL-1R1hi and IL-1R1lo subpopulations of stage 3 iNK cells. ‘‘Fold difference’’
was quantified relative to expression in the IL-1R1lo subpopulation, arbitrarily normalized to 1 (p% 0.05). Data in (D) are presented as mean ± SEM (n = 6).
(E) Using gating as indicated in (A), histograms depict a representative donor stained ex vivo with isotype (unfilled) or antibody specific for the indicated antigen
(filled), within total stage 3 iNK cells or IL-1R1hi and IL-1R1lo subpopulations of stage 3 iNK cells (nR 4). The IL-1R1CD117 and IL-1R1+CD117 subsets noted
in (A) were both nonreactive for intracellular IL-22 protein staining.
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clear cells indicated that IL-1R1 surface expression identifies
two distinct subpopulations of stage 3 iNK cells: an IL-1R1hi
subpopulation and an IL-1R1lo subpopulation. We discovered
that expression of IL-22 protein was restricted to IL-1R1hi stage
3 iNK cells, which were uniformly IL-22+. In contrast, the minor
populationof IL-1R1lo stage3 iNKcellswas IL-22. Adonor repre-
sentative of five such analyses is shown in Figures 2A–2C. With
this in mind, wemeasured IL-22, AHR, andRORCmRNA expres-
sion within sorted resting IL-1R1hi and IL-1R1lo subpopulations of
stage 3 iNK cells. Expression of IL-22 and AHR transcripts was
restricted to the IL-1R1hi subpopulationof stage3 iNKcells,where
they were present at amounts at least 22 ± 5.75-fold and 3439 ±
860-fold higher, respectively, than those seen in the IL-1R1lo
subpopulationof stage3 iNKcells (Figure2D). In contrast, expres-
sion of the LTi-associated transcription factor RORC, which isrestricted to the stage 3 iNK cells in SLT (Cupedo et al., 2009),
could be detected in both the IL-1R1hi and IL-1R1lo subpopula-
tions of stage 3 iNKcells, aswere theNK lineage-associated tran-
scription factors E4BP4 and Ets-1 (Figures S2A–S2C). Flow
cytometry revealed that expression of CD127, CD56, CD161,
NKp44, CCR7, and LT-a—associatedwith the LTi-like phenotype
(Cupedo et al., 2009)—are also relatively restricted to the IL-1R1hi
subpopulation of stage 3 iNK cells (Figure 2E). Together, our data
suggest that IL-22 andAHR are specific to the IL-1R1hi subpopu-
lation of resting human stage 3 iNK cells from SLT and that these
cells also share the phenotype of LTi-like cells.
Human IL-1R1hi Stage 3 iNK Cells Selectively Display
a Functional Response to IL-1b
To explore the functional relevance of differential IL-1R1 expres-
sion in human NK cell development, we isolated stage 1–4 NKImmunity 32, 803–814, June 25, 2010 ª2010 Elsevier Inc. 805
Figure 3. Treatment with IL-15 and IL-1b Promotes the Selective
Expansion of Stage 3 iNK Cells
(A and B) ‘‘Fold change’’ was calculated and averaged from 11 donors as the
absolute number of cells enumerated (by Trypan blue exclusion) after 14 days
of culture in IL-15 and IL-1b divided by the absolute number of cells enumer-
ated after 14 days of culture in IL-15 alone. For example, starting with
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806 Immunity 32, 803–814, June 25, 2010 ª2010 Elsevier Inc.developmental intermediates from SLT via flow cytometry and
treated each with exogenous IL-1b, a physiologic ligand for
this receptor. Not surprisingly, given that IL-15 has been demon-
strated to serve as a survival factor during NK cell development
(Huntington et al., 2009), cells treated with IL-1b alone were
uniformly dead after 48 hr, regardless of stage. However, when
compared to cells from the same stage and donor cultured
with IL-15 alone, the combination of IL-15 and IL-1b led to an
expansion in the number of viable stage 3 iNK cells when exam-
ined after 2, 7, or 14 days. Notably, IL-1b expanded stage 3 iNK
cells to 4.7 ± 0.7-fold relative to the quantity of cells generated
after 14 days with IL-15 alone (Figure 3A). The expansion in the
presence of IL-15 and IL-1b was diminished after withdrawal of
IL-1b starting at day 7 of culture (data not shown). Likewise,
culture of stage 3 iNK cells in the continuous presence of a
100-fold molar excess of IL-1 receptor antagonist (IL-1RA),
a naturally occurring specific competitive inhibitor of IL-1b
binding to IL-1R1 (Arend et al., 1991), completely abrogated
the IL-1b-mediated expansion observed earlier (Figure 3B).
We determined that this IL-1b-induced expansion of stage
3 iNK cells resulted from enhanced proliferation rather than
survival (Figure 3C). Notably, despite modest yet measurable
amounts of IL-1R1 surface expression, the addition of IL-1b
did not substantially affect proliferation of stages 1, 2, or 4. Like-
wise, parallel cultures comparing IL-1R1hi and IL-1R1lo subpop-
ulations of stage 3 iNK cells revealed that, whereas IL-15 alone
maintained survival of both IL-1R1hi and IL-1R1lo subpopulations
of stage 3 iNK cells in vitro, the addition of IL-1b enhanced prolif-
eration of the IL-1R1hi, but not the IL-1R1lo, subpopulation of
stage 3 iNK cells (Figure 3D).IL-1b Sustains Expression of IL-22 and AHR in IL-1R1hi
Stage 3 iNK Cells
To explore the potential role of IL-1b in regulating expression of
IL-22 and AHR, which are restricted to IL-1R1hi stage 3 iNK cells
ex vivo, we measured expression of each transcript after in vitro
exposure to IL-15 or IL-15 and IL-1b. Whereas IL-22 and AHR
mRNA all but disappeared in the presence of IL-15 alone, expo-
sure to IL-1b preserved IL-22 and AHR expression in total stage
3 iNK cells (Figures 4A and 4B). Furthermore, IL-22 and AHR
remained restricted to the IL-1R1hi stage 3 iNK subpopulation,
which also required exposure to IL-1b for continued expression
in vitro (Figures 4C and 4D). In contrast, culture in the presence or
absence of IL-1b resulted in similar expression of RORCmRNA,
which was sustained in IL-1R1lo and IL-1R1hi subpopulations of
stage 3 iNK cells and induced in stage 4mature NK cells (Figures
S3A–S3C). These correlative data suggest that human stage 35,000 stage 3 iNK cells/well, four representative donors cultured in IL-15 and
IL-1b expanded to 90,000, 285,000, 162,000, and 40,000, whereas the same
four donors’ stage 3 iNK cells cultured in IL-15 alone expanded to 20,000,
55,0000, 45,000 and 10,000 cells, respectively. Results revealed a selective
growth advantage among stage 3 iNK cells in response to culture with IL-15
and IL-1b (**p < 0.005; n = 11) (B), whichwas completely abrogated in the pres-
ence of IL-1 receptor antagonist (IL-1RA) (p < 0.05; n = 4).
(C and D) Proliferation assessed via 5-ethynyl-2’-deoxyuridine (EdU) incorpo-
ration in total stage 3 iNK cells (p < 0.05; n = 8) (C) or IL-1R1hi and IL-1R1lo
subpopulations of stage 3 iNK cells (*p = 0.01; n = 3) (D) after culture for
14 days in the presence of IL-15 or IL-15 and IL-1b. Data in (A)–(D) are depicted
as mean ± SEM.
Figure 4. IL-1b Sustains IL-22 and AHR Expression in IL-1R1hi Stage 3 iNK Cells
(A–D) IL-22 and AHR transcript expression following 14 days in the presence of IL-15 or IL-15 and IL-1b, shown in total (‘‘bulk’’) stage 3 iNK cells (A and B) or the
IL-1R1hi subpopulation of stage 3 iNK cells (C and D). Results are depicted as the mean ± SEM, p% 0.05 in each (nR 4).
(E) Dot plots depict surface IL-1R1 and intracellular staining with IL-22 or isotype antibody in IL-1R1hi stage 3 iNK cells from a representative donor cultured for
14 days in the presence of IL-15 or IL-15 and IL-1b (n = 6). All IL-22+ cells coexpressed IL-1R1.
(F) Histograms from a representative donor (n = 4) depict stainingwith IL-22 (filled) or isotype (unfilled) antibody in the IL-1R1hi subpopulation of stage 3 iNK cells at
day 0 and within IL-1R1+ cells remaining after culture for 14 days with IL-15 and IL-1b.
(G) IL-1R1 MFI assessed via flow cytometry after a 6 hr culture in the presence of IL-15 or media alone (n = 3).
(H) Representative staining for surface CD94 and intracellular IL-22 protein at day 14 in cells cloned from either a single IL-1R1lo stage 3 iNK cell or an IL-1R1hi
stage 3 iNK cell. Isotype staining is on the far right.
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IL-1b Expands and Sustains IL-22+ iNK CellsiNK cell production of IL-22 may be more dependent on the
expression of AHR than RORC, as has recently reported for
IL-17IL-22+ human T cells (Trifari et al., 2009).
Although culture of IL-1R1hi stage 3 iNK cells for 14 days in IL-
15 and IL-1b resulted in a decrease in the overall number of cells
expressing IL-1R1 and the overall expression of IL-22, IL-22 re-
mained restricted to progeny that were also IL-1R1+ (Figures 4E
and 4F). Declining numbers of IL-1R1+ progeny during culture in
IL-15 and IL-1b was not due to overgrowth of the minor IL-1R1lo
subpopulation of stage 3 iNK cells (Figure 3D), but rather resulted
from an IL-15-mediated decrease in IL-1R1 on the surface of IL-1R1hi stage 3 iNK cells (Figure 4G). Furthermore, we assessed
the clonal outgrowth from single IL-1R1hi and IL-1R1lo stage
3 iNK cells and found that the capacity for sustained expression
of IL-22 remained restricted to the progeny of IL-1R1hi stage
3 iNK cells and exclusive of CD94 expression (Figure 4H;
Table S1). Thus, IL-22+ cells derived in vitro appear to have
been generated exclusively from the IL-1R1hi subpopulation.
Together, our data suggest that continued expression of IL-22
by stage 3 iNK cells in vitro is dependent on exposure to IL-1b
and that IL-22 expression remains restricted to the IL-1-respon-
sive subpopulation of IL-1R1hi stage 3 iNK cells.Immunity 32, 803–814, June 25, 2010 ª2010 Elsevier Inc. 807
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iNK Cells
IL-15 promotes the differentiation of stage 3 iNK cells to stage 4
mature NK cells, which are characterized by coexpression of
CD94 and high-density CD56, as well as the potential for
IFN-g production and cytolytic activity (Freud et al., 2006;
Huntington et al., 2009; Sanos et al., 2009). If IL-1b expands
stage 3 iNK cells for the purposes of sustaining IL-22 expres-
sion and mucosal immunity, it should also inhibit differentiation
to stage 4 mature NK cells. With this in mind, we assessed
expression of CD94 and CD56 via flow cytometry after culture
of stage 3 iNK cells, either in bulk or, as IL-1R1hi and IL-1R1lo
subpopulations, with IL-15 alone or IL-15 and IL-1b. The pres-
ence of IL-1b conferred a 50% decrease in the proportion of
stage 3 iNK cells that progressed to stage 4 mature NK cells,
as measured by CD94 acquisition (Figure 5A; 11.3% ± 2.7%
with IL-1b versus 21.7% ± 2.1% with IL-15 alone), and
a concomitant 3.02 ± 0.4-fold decrease in MFI of CD56 surface
expression (Figure 5B). These effects, which could be observed
within 2 days of in vitro culture, were restricted to IL-1R1hi stage
3 iNK cells and were not seen in cultures of the IL-1R1lo subset
(Figures 5C–5E) or in cells from stages 2 or 4 (data not shown).
Inclusion of a molar excess of IL-1RA in cultures containing
IL-15 and IL-1b fully restored acquisition of CD94 (Figure 5F)
and density of CD56 surface expression (Figure 5G). Figure 5H
shows additional maturation markers assessed in IL-1R1hi
stage 3 iNK cells cultured for 14 days in IL-15 or IL-15 and
IL-1b.
IL-1b Inhibits the Functional Maturation of Human
IL-1R1hi Stage 3 iNK Cells
We next assessed whether treatment of human stage 3 iNK cells
with IL-15 and IL-1b also inhibited the acquisition IFN-g produc-
tion and cytotoxic activity seen in stage 4 mature NK cells.
Freshly isolated human stage 3 iNK cells do not produce IFN-g
or display natural cytotoxicity against K562 target cells (Freud
et al., 2006). Indeed, stage 3 iNK cells incubated in vitro with
IL-15 and IL-1b for 14 days produced negligible amounts of
IFN-g (100 pg/ml) after coactivation with IL-12, IL-15, and IL-
18. In contrast, stage 3 iNK cells incubated in vitro with IL-15
alone for 14 days produced substantial IFN-g, averaging 3167 ±
734 pg/ml, following coactivation with IL-12, IL-15, and IL-18
(Figure 6A). As shown in Figure 6B, this IL-1b-mediated reduc-
tion in IFN-g production was restricted to the IL-1R1hi subpopu-
lation of stage 3 iNK cells. As judged by effector cytokine secre-
tion, exposure to IL-1b inhibited the functional maturation of
stage 3 iNK cells.
Although the capacity to secrete IFN-g was restricted to the
population that had acquired surface expression of CD94
in vitro (Figure S4A), surface expression of the degranulation
marker CD107a, which can be used as a functional marker to
identify cytotoxic NK cells (Alter et al., 2004), was observed in
both CD94+ and CD94 cells generated from culture of stage 3
iNK cells in vitro (Figure S4B). Surface expression of the degran-
ulation marker CD107a indicated that, compared to bulk stage 3
iNK cells cultured with IL-15 alone, bulk culture of stage 3 iNK
cells in the presence of IL-15 and IL-1b for 14 days did not signif-
icantly influence CD107a surface expression (Figure 6C;
p = 0.14); however, exposure to IL-15 and IL-1b significantly808 Immunity 32, 803–814, June 25, 2010 ª2010 Elsevier Inc.reduced degranulation within the IL-1R1hi subpopulation of
stage 3 iNK cells (Figure 6D; p = 0.01).Human Stage 3 iNK Cells Proliferate in Direct Response
to Proximate cDC-Derived IL-15 and IL-1b
To identify potential physiological sources of IL-1b that may
interact with stage 3 iNK cells, we used flow cytometry to analyze
fresh SLT mononuclear cells for intracellular IL-1b. Although we
detected low intracellular IL-1b in a modest fraction of CD3+
T cells and CD14+ monocytes and macrophages (Figure 7A),
IL-1b expression occurred in a large portion of tonsillar
CD11chiCD123lo cDCs (Figures 7B and 7C, top). In contrast,
CD11cloCD123hi plasmacytoid DCs (pDCs) and the population
of CD11cloCD123lo cells did not contain intracellular IL-1b
(Figure 7B and data not shown, respectively).
Stage 3 iNK cells were previously identified in situ as CD117+
cells with lymphoid morphology and localized to the lamina
propria or the parafollicular T cell-rich region of the tonsil
(Hughes et al., 2009). These CD117+ stage 3 iNK cells, which
are primarily CD161+IL-1R1hiIL-22+ (Figure 2; Figure S5), were
found to be located in close proximity to IL-1b-producing
CD11chi cDCs in the parafollicular T cell-rich region of human
tonsil (Figure 7C, bottom). Thus, tonsillar cDCs appear to be
a plausible cellular source of IL-1b for human stage 3 iNK cells
in vivo.
Indeed, compared to parallel cultures performed in the
absence of cDCs, short-term coculture of IL-1R1hi stage 3 iNK
cells with autologous BDCA-1+CD11chiCD123lo cDCs enhanced
proliferation (measured via 5-ethynyl-20-deoxyuridine [EdU]
incorporation assay) of IL-1R1hi stage 3 iNK cells, but not of IL-
1R1lo stage 3 iNK cells (Figure 7D). Although neither a-IL-15
nor a-IL-1b antibodies altered EdU incorporation as a single
blocking reagent (data not shown), addition of a-IL-15 and
a-IL-1b antibodies together reduced EdU incorporation to
amounts seen in the absence of cDCs, implicating specific roles
for cDC-derived IL-15 and IL-1b in the proliferative response
observed in IL-1R1hi stage 3 iNK cells (Figure 7D). Thus, cDC-
derived IL-15 and IL-1b are capable of directly stimulating prolif-
eration of IL-1R1hi stage 3 iNK cells. Similar costimulatory effects
may also be possible between IL-1R1hi stage 3 iNK cells and IL-
1b-producing CD14+ monocytes or macrophages that also
produce IL-15.DISCUSSION
Here we identify a role for IL-1R1 and its cognate ligand, IL-1b, in
the homeostasis of stage 3 iNK cells, which selectively
expressed IL-1R1 compared to other NK developmental inter-
mediates residing in human tonsil. In the presence of IL-15,
binding of IL-1b to IL-1R1 expanded IL-1R1hi stage 3 iNK cells
and preserved expression of IL-22 and AHR. In contrast, culture
of IL-1R1hi stage 3 iNK cells in IL-15 alone resulted in a loss of IL-
22 and AHR expression and enhanced differentiation toward
IFN-g-producing stage 4 mature NK cells. Furthermore,
CD117+ cells, which coexpress CD161 and IL-22 and thus corre-
spond to the IL-1R1hi subpopulation of stage 3 iNK cells, reside
in the lamina propria and parafollicular T cell-rich area of human
tonsil and colocalized with a cellular source of IL-1b found in
Figure 5. IL-1b Inhibits Differentiation of IL-1R1hi Stage 3 iNK Cells
(A–E) Surface expression of CD94 (A, D, and E) and CD56 (B and C) assessed after 14 days of in vitro culture of sorted total (A and B) or IL-1R1hi and IL-1R1lo
subpopulations of stage 3 iNK cells (C, D, and E) with IL-15 or IL-15 and IL-1b.
(F and G) CD94 and CD56 were also assessed after bulk stage 3 iNK cells were cultured for 14 days in the presence of IL-15, IL-15 and IL-1b, or IL-15 with IL-1b
and IL-1RA.
(H) Histograms depict staining with isotype (unfilled) or antibody specific for the indicated antigen (filled) after culture of IL-1R1hi stage 3 iNK cells for 14 days in the
presence of IL-15 or IL-15 and IL-1b. Arrows indicate high-density expression for IL-1R1 and IL-22 (see also Figure 4F).
Data in (A), (B), and (E–G) are presented as the mean ± SEM (*p% 0.05; nR 4). Histograms in (C), (D), and (H) depict staining in a representative donor (nR 4).
Immunity
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IL-1b-IL-1R1 interaction in vivo.
RORC is a hallmark of mature Th17 cells (Ivanov et al., 2006)
but has also been detected in murine FOXP3+ regulatory
T (Treg) cells (Lochner et al., 2008) and human FOXP3+ Treg
cells (Ayyoub et al., 2009). Indeed, unstimulated human stage
3 iNK cells in SLT express RORC and AHR mRNA (Cupedoet al., 2009), IL-22 protein (Hughes et al., 2009), and, as we
establish here, IL-1R1. Although IL-1b appears to be required
by human stage 3 iNK cells for continued expression of IL-22
and AHR in vitro, other LTi-associated genes—IL-26 and
RORC—were maintained in stage 3 iNK cells by IL-15 alone.
Furthermore, culture of stage 4 mature NK cells in the presence
of IL-15 induced expression of RORC in vitro, suggesting thatImmunity 32, 803–814, June 25, 2010 ª2010 Elsevier Inc. 809
Figure 6. IL-1b Impedes the IL-1R1hi
Subpopulation of Stage 3 iNK Cells from
Acquiring IFN-g Production and Degranula-
tion
(A–D) Total (A and C) or IL-1R1hi and IL-1R1lo
subpopulations (B and D) of stage 3 iNK cells
sorted from SLT were cultured for 14 days
in vitro with IL-15 or IL-15 and IL-1b. Cells were re-
plated in equal numbers and either stimulated for
12 hr with IL-15 + IL-12 + IL-18 to assess IFN-g
secretion via enzyme-linked immunosorbent
assay (p < 0.005; n = 7) (A) or intracellular flow
(n = 8) (B) or incubated overnight with K562 targets
(4:1 E/T ratio) and assessed for surface expres-
sion of the degranulation marker CD107a by
flow cytometry (C and D; n = 3; for C, p = 0.14).
Data in (B) depicts IFN-g expression after gating
on the population that had acquired CD94 surface
expression. Data are presented as mean ± SEM
(*p% 0.01).
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that are dependent upon IL-1b for continued expression, espe-
cially within human stage 3 iNK cells. This is consistent with
our observation that, unlike IL-22 and AHR, constitutive expres-
sion of RORC is not restricted to the IL-1R1hi subpopulation of
stage 3 iNK cells. It is also consistent with the observation that
MALT develops in the murine tear duct independently of RORC
expression (Nagatake et al., 2009).
Murine studies indicate that RORC+CD127+NKp46+NK1.1+
cells are decreased in the setting of IL-15 gene deficiency, as
well as in animals lacking the IL-2 receptor beta chain (IL-2Rb,
CD122) (Satoh-Takayama et al., 2008), which is required for IL-
2 and IL-15 signaling. However, this population is absent in IL-
2Rg-deficient animals that cannot respond to any of the so-
called gc cytokines (Vosshenrich et al., 2005). Situations have
been reported in which IL-2 or IL-7 may be substituted in place
of IL-15 (Cupedo et al., 2009; Freud et al., 2006; Satoh-Ta-
kayama et al., 2010; Satoh-Takayama et al., 2008). Given that
nearly all human stage 3 iNK cells—as well as the equivalent
RORC+NKp46+NK1.1int murine population—express CD127
(Luci et al., 2009), the role of IL-7 deserves particular attention.
Compared to IL-2 or IL-15, IL-7 alone was much less potent at
maintaining stage 3 iNK cell survival in vitro. Furthermore, stage
3 iNK cells cultured with IL-2 or IL-15 did not significantly differ
qualitatively or quantitatively compared to parallel cultures sup-
plemented with IL-7. This is in agreement with murine studies
indicating that IL-7- and IL-7Ra-deficient mice do not exhibit
NK developmental defects (Maki et al., 1996; Vosshenrich
et al., 2005). It remains possible that this cytokine plays a role
in regulating additional functions of this population in SLT,810 Immunity 32, 803–814, June 25, 2010 ª2010 Elsevier Inc.such as the LTi-like behavior that has
been reported in human stage 3 iNK pop-
ulation (Cupedo et al., 2009).
Both human Th17 cells and stage 3 iNK
cells produce IL-22 (Cella et al., 2009)
and express the transcription factors
RORC and AHR (Cupedo et al., 2009).
Murine Th17 cells have higher expressionof IL-1R1mRNA than is seen in Th1 or Th2 cells, and exposure to
IL-1b promotes Th17 cell proliferation, differentiation, and
expression of IL-17 and RORC (Chung et al., 2009). Like Th17
cells (Chung et al., 2009; Rao et al., 2007; Veldhoen et al.,
2008), the IL-1R1hi subpopulation of stage 3 iNK cells selectively
expresses AHR, expands upon in vitro treatment with IL-1b, and
depends on IL-1b for expression of AHR and IL-22. We also
noted that expression of IL-1R1 on stage 3 iNK cells diminishes
over time during in vitro culture with a proportional decrease in
IL-22 expression, and we show that this downregulation of
IL-1R1 is mediated by IL-15. This observation lends further
support to our notion that, in vivo, constitutive expression of
IL-22 in stage 3 iNK cells likely requires coexpression of IL-1R1
and proximity to cells expressing its cognate ligand, IL-1b.
In addition to IL-1b, we investigated the role of IL-23, which did
not markedly alter the quantity of cells generated in vitro from
stage 3 iNK cells, whether cultured in the presence of IL-15 or
IL-15 and IL-1b. IL-23 acts on human Th17 cells to promote
expression of Th17 cell-associated genes, such as IL-22 (Zheng
et al., 2007), RORC, and IL-26 (Manel et al., 2008). We did not
observe any marked effect on IL-22, IL-26, or RORC expression
when stage 3 iNK cells were culturedwith IL-23, regardless of the
presence of IL-15 or IL-15 and IL-1b. Together, these findings
suggest that distinct repertoires of cytokines regulate the devel-
opment of human Th17 cells and stage 3 iNK cells found in SLT.
Unabated expression of proinflammatory cytokines can lead
to chronic inflammatory states, autoimmune disease, and
cancer. IL-1b production is subject to intense regulation at the
level of its synthesis and excretion. Its interaction with IL-1R1
is further regulated by competitive inhibition by IL-1RA (Carter
Figure 7. Stage 3 iNK Cells Reside in the
Vicinity of IL-1b+ CD11chi cDCs within SLT
(A and B) Intracellular flow cytometric staining of
unstimulated SLTmononuclear cells from a repre-
sentative donor (n = 3) with isotype (unfilled) or
a-IL-1b (filled) antibody, shown after gating on
CD45+CD3+ T cells and CD45+CD14+ monocytes
and macrophages (A) or CD123hiCD11clo pDCs
and CD123loCD11chi cDCs subsets (B).
(C) Immunohistochemical staining depicted in
serial sections of human tonsil from a representa-
tive donor (n = 4). Yellow areas indicate coexpres-
sion, as shown for CD11chi and IL-1b (top).
CD117+ cells did not coexpress CD11c but were
located in proximity of CD11chi cDCs (bottom).
Magnification is 4003. Scale bar represents
30 mM.
(D) EdU incorporation in sorted IL-1R1hi and IL-
1R1lo subpopulations of stage 3 iNK cells after
6 hr with a-MEMmedium alone or in the presence
of autologous BDCA-1+ cDCs (4:1 iNK:cDC ratio)
with either isotype or a-IL-15 and a-IL-1b blocking
antibodies. Depicted is the percentage of CD117+
lymphocytes that were also EdU+ (*p = 0.05;
n = 3). Data in (D) are presented as mean ± SEM.
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(Colotta et al., 1993). We found that IL-1RA is capable of fully
neutralizing the impact of IL-1b on IL-1R1hi stage 3 iNK cell prolif-
eration and on in vitro differentiation toward CD94+ stage 4 NK
cells. Similarly, IL-22 signaling triggers expression of a naturally
occurring antagonist, IL-22-binding protein (IL-22BP), which
binds IL-22 to prevent signaling through IL-22R (Dumoutier
et al., 2001). These regulatory pathways serve to quickly and
precisely adjust biological responses to IL-1b and IL-22. Indeed,
the assessment of anti-IL-1b therapy might be considered in
illnesses such as Crohn’s disease and psoriasis, where exces-
sive IL-22 production is felt to be pathological (Kleinschek
et al., 2009; Wilson et al., 2007). Ablation of IL-1R1 signaling
should enhance NK cell differentiation and diminish IL-22
production from the IL-1R1hi stage 3 iNK cell population.
Excessive inflammation can disrupt SLT architecture, necessi-
tating local tissue regeneration for restoration of the SLT micro-
environment (Kratz et al., 1996). LTi cells have a proposed role in
reestablishing the integrity of lymphoid tissues following chronic
infections (Scandella et al., 2008). Cupedo et al. first identified
RORC+ LTi-like cells in human fetal lymph node as committed
iNK cells expressing IL-22, CD117, CD127, LT-a, and CCR7
(Cupedo et al., 2009). A study by Crellin et al. provides strongImmunity 32, 803–8evidence that LTi-like activity is most
robust within a subset of cells coexpress-
ing CD127 and CD161 (Crellin et al.,
2010). We found that the IL-1R1hi
subpopulation of iNK cells possesses
a strikingly similar phenotype. Among
total stage 3 iNK cells, the IL-1R1hi
subset is enriched for cells coexpressing
CD127, CD161, LT-a, CCR7, and IL-22.
As we observed in the IL-1R1hi subpopu-
lation of stage 3 iNK cells, Crellin et al.reported that CD127+ LTi-like cells varied in expression of
CD56 and NKp44 and contained cells capable of giving rise to
cytotoxic mature NK cells in the presence of IL-15 in vitro.
They reported that, compared to the CD127 subpopulation,
the CD127+ subpopulation is reduced in its propensity to
generate mature NK cells in IL-15. Our study shows a reduced
propensity to generate mature NK cells when IL-1b was added
to culture of IL-1R1hi stage 3 iNK cells in the presence of IL-15.
These data suggest that the developmental relationship between
the CD127+IL-1R1hi, CD127+IL-1R1lo, CD127IL-1R1hi, and
CD127IL-1R1lo populations will need to be explored in future
studies. They also serve to emphasize the heterogeneity within
the CD117+CD161+IL-1R1hi stage 3 iNK cell population and
the need for caution in assigning definitive functions and devel-
opmental potential.
We previously reported limited differentiation of stage 3 iNK
cells to CD94+ stage 4 NK cells with IL-15 in vitro (5%–20%
[Freud et al., 2006]), but the developmental relationship between
stage 3 iNK cells and CD94+ stage 4 NK cells remained unclear
and was pursued in this study. The current report describes two
subpopulations of stage 3 iNK cells distinguished by surface
expression of functional IL-1R1. Predictably, the presence of
IL-1b in culture had no appreciable effect on differentiation of14, June 25, 2010 ª2010 Elsevier Inc. 811
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IL-1b Expands and Sustains IL-22+ iNK CellsIL-1R1lo stage 3 iNK cells, but during culture of IL-1R1hi stage 3
iNK cells, IL-1b limited maturation to stage 4 NK cells and sus-
tained expression of AHR and IL-22 mRNA, as well as IL-22
protein in the remaining IL-1R1hi stage 3 cells. In the absence
of IL-1b, culture of IL-1R1hi stage 3 iNK cells with IL-15 had
a significantly greater propensity to mature into CD94+CD56bright
stage 4 NK cells.
These findings support the hypothesis that the human stage
3 iNK cell population (CD3CD34CD117+CD161+CD94)
consists of a minor IL-1R1lo subset that does not express
IL-22, as well as an IL-1R1hi subset that constitutively expresses
IL-22 yet can also give rise to CD94+ mature NK cells. The
CD117+IL-1R1lo stage 3 iNK cell may acquire IL-1R1 and then,
under some circumstances, proceed to a CD94+CD56bright stage
4 mature NK cell, or it may bypass the acquisition of IL-1R1. The
proportion of IL-1R1hi stage 3 iNK cells that differentiate to
CD94+CD56bright stage 4 mature NK cells relative to those that
continue to express IL-22 appears to be dependent on their
continued expression of IL-1R1, as well as their exposure to
IL-1b. The regulation of the IL-1R1 by IL-15, and the regulation
of exposure to its ligand IL-1b by cell-cell interactions andmicro-
bial invasion, may dictate the relative abundance of the
CD117+IL-1R1hi stage 3 iNK and the CD94+CD56bright stage
4 mature NK cell in SLT. Finally, this study identifies a stage
3 iNK subpopulation in human tonsil as an innate immune target
of IL-1b and provides a mechanistic connection between IL-1b
and IL-22 production, with implications for mucosal innate
immunity.EXPERIMENTAL PROCEDURES
Isolation of Human NK Precursors from SLT
All protocols were approved by The Ohio State University Institutional Review
Board. Normal human tonsils were obtained within 24 hr of elective surgery
through the National Cancer Institute-Sponsored Cooperative Human Tissue
Network and the Biopathology Center at Nationwide Children’s Hospital. NK
cell developmental intermediates were isolated as described (Freud et al.,
2006). Briefly, mononuclear fractions were depleted of CD3+ and CD19+ cells
via magnetic negative selection (Miltenyi). For certain experiments, T and B
cell-depleted preparations were stained immediately for phenotypic analyses.
Alternatively, CD34+ cells were enriched from CD3CD19 cells using a CD34
progenitor isolation kit (Miltenyi) for flow cytometric sorting of stage 1 and 2
cells, whereas total stage 3 iNK cells and stage 4 NK cells were sorted from
the CD34 fraction as previously described (Freud et al., 2006). IL-1R1hi and
IL-1R1lo stage 3 iNK subpopulations were isolated from the CD34 fraction
using surface staining with goat a-IL-1R1 and a-goat Allophycocyanin (APC,
R&D Systems), in addition to the previously described stage 3 cell-surface
antigens (Freud et al., 2006). Populations were sorted to purity R95% with
a FACSAria II cell sorter (BD Biosciences).
Flow Cytometry
All antibodies used for flow cytometry were purchased from BD Biosciences
except BDCA-1 (Miltenyi), CD56, CD127, CD161, NKp44, NKp46 (Beckman
Coulter), goat IgG (Santa Cruz), CD94 (clone 131412), IL-22 (clone 142928),
IL-1R1 (MAB269), and a-goat APC (R&D Systems). Unless otherwise indi-
cated, antibodies were used according to manufacturers’ instructions.
Nonspecific staining was detected through the use of an appropriately labeled
isotype antibody. IL-1R1 staining was performed on ice for 15 min with a-IL-
1R1 or goat IgG (1 mg/105 cells) in parallel with any additional directly conju-
gated antibodies indicated. Samples were washed and then incubated on
ice for 30 min with a-goat APC (0.25 mg/105 cells). Intracellular staining was
performed after surface staining using the BD Cytofix/Cytoperm Plus Fixa-
tion/Permeabilization Kit (BD Biosciences). Ex vivo staining was performed812 Immunity 32, 803–814, June 25, 2010 ª2010 Elsevier Inc.without additional stimulation, and in the absence of brefeldin A, immediately
following CD3 and CD19 depletion. Intracellular staining after culture was per-
formed following 4 hr incubation with 2 mM GolgiPlug (BD Biosciences). Intra-
cellular staining for IL-1b was performed according to the manufacturer’s
instructions, and IL-22 staining was as previously described (Hughes et al.,
2009). Cells were analyzed immediately as previously described (Freud
et al., 2005) using a FACSCalibur or BD LSR II cytometer (BD Biosciences).
Real-Time PCR
RNA was obtained by lysing a portion of each sorted population in approxi-
mately equal quantity (R1 3 104 cells). For some experiments, RNA was
also obtained after 14 days in vitro culture. Samples from %5 3 104 cells
were processed using Absolutely RNA Nanoprep Kit (Stratagene); samples
with R5 3 104 cells were processed using RNeasy (QIAGEN). cDNA was
synthesized according to manufacturer’s instructions using MMLV reverse
transcriptase kit (Invitrogen). Real-time PCR was performed on an ABI Prism
7900HT (Applied Biosystems) using Taqman primer/probe sets for IL-22,
AHR, and IL-1R1, purchased from Applied Biosystems. Expression levels
were normalized to an 18S internal control and then analyzed by the DDCt
method (Fehniger et al., 1999).
Cell Culture
Flow cytometry purified NK developmental intermediates were cultured in
a round-bottom 96-well plate (Costar) at a starting density of 25,000 cells/ml
in a-MEM medium containing 10% fetal bovine serum, penicillin G
(100 mg/ml), and streptomycin (100 mg/ml) (Invitrogen). Cells from stages 2–4
were cultured in the indicated recombinant human cytokines, including IL-15
(1 nM; Amgen), IL-1b (10 ng/ml; Peprotech), and IL-1RA (100 ng/ml; R&D
Systems). Medium for stage 1 cells was also supplemented with IL-7
(10 ng/ml), IL-3 (10 ng/ml; R&D Systems), and FL (100 ng/ml; Peprotech).
For cultures lasting more than 24 hr, half of the medium was removed every
2–3 days and replaced with media containing 23 cytokines.
Clonal Assays
FACSAria II was used to deposit single IL-1R1hi or IL-1R1lo stage 3 iNK cells
directly into each well of a 96-well flat-bottom plate containing GFP+ murine
OP9 stroma in a-MEM medium containing IL-15 + IL-1b. After 14 days, each
of 60 replicate wells was individually assessed via flow cytometry for human
CD45 andCD94 surface expression, in addition to intracellular IL-22. OP9 cells
were excluded by gating on GFP events expressing human CD45.
Proliferation Assays
Click-iT EdU kit (Invitrogen) was used according tomanufacturer’s instructions
to assess proliferation of stage 3 iNK cells purified via flow cytometry, either in
bulk or, as IL-1R1hi and IL-1R1lo subpopulations, in response to cDC-derived
or recombinant IL-15 or IL-15 and IL-1b. After CD3 and CD19 depletion, SLT
cDCs were enriched via magnetic selection using BDCA-1-biotin antibody
and a-biotin microbeads (Miltenyi). Purity was R87% via flow cytometric
staining. Autologous IL-1R1hi and IL-1R1lo stage 3 iNK subpopulations were
sorted via flow cytometry from BDCA-1-depleted fractions. Cocultures were
performed at 4:1 iNK:cDC ratio. After 6 hr in the presence of 5 mM EdU, the
proportion of CD117+ cells positive for EdU uptake (corresponding to DNA
replication and S phase of the cell cycle) was assessed via flow cytometry.
Controls included cells cultured in the absence of EdU and samples without
AlexaFluor 488 azide (used to fluorescently label EdU). Additional controls
included for cDCs cocultures included iNK cell monocultures performed in
media alone or in media with recombinant IL-15 and IL-1b. For neutralization
experiments, iNK/cDC cocultures were performed in the presence of a-IL-15
(1 mg/ml) and/or a-IL-1b (0.5 mg/ml) blocking antibodies (R&D Systems) and/
or an equal concentration of isotype IgG (Santa Cruz).
Effector Function Assays
After 14 days of culture with IL-15 or IL-15 and IL-1b, cells were counted and
replated in equal numbers for each assay. Surface staining for CD107a,
a degranulation marker used to identify cytotoxic NK cells (Alter et al., 2004),
was assayed via flow cytometry as previously described (Betts et al., 2003)
in response to 8 hr incubation with K562 target cells (4:1 E/T ratio). IFN-g
secretion, in response to 12 hr stimulation with recombinant monokines
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IL-1b Expands and Sustains IL-22+ iNK Cells(IL-15with IL-12 [10 ng/ml; Genetics Institute] and IL-18 [50 ng/ml; BASF]), was
measured as previously described via intracellular flow cytometry (Cooper
et al., 2001) or enzyme-linked immunosorbent assay (detection limit 10–30
pg/ml) using commercial antibody pairs (Endogen) (Trotta et al., 2005).
Controls for effector function assays included staining with isotype control
antibody and parallel cultures performed in the absence of K562 ormonokines.
Immunohistochemical Staining
Immunohistochemistry was performed on human tonsils as previously
described (Fehniger et al., 2003). The ultraView Universal system (Ventana
Medical) was employed to assess paraffin-embedded tonsillar tissue in serial
sections (0.5 mM) stained with the indicated antibodies, including a-CD117
(1:500; DakoCytomation), a-IL-1b (1:50), and a-CD11c (1:100, Abcam).
Images were digitally acquired using a DP 12 camera, a BX50 microscope,
and UPLANF1 objectives (Olympus) and were analyzed using Photoshop
CS3 software (Adobe). The Nuance FX system (Cambridge Research & Instru-
mentation) digitally converted staining with DAB or fast red to fluorescent
green or red, respectively. Using the Nuance System’s multispectral image
analysis, we were able to identify both CD11chi and CD11clo cells. Subse-
quently, the threshold of signal strength, corresponding specifically to the
CD11c chromagen, was increased to display only the CD11chi cells within
tissue sections.
Statistical Analysis
To compare two conditions, we analyzed data using paired t tests. Linear
mixed models were used for analysis when more than two treatment condi-
tions were used. All tests were two sided. Holm’s method was used to correct
formultiple comparisonswhen needed. p < 0.05was considered significant for
single comparisons, after adjustment for multiple comparisons.
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